Why Your GTM Strategy Needs a Clinical Layer
If you sell into healthcare, you already know the sales cycle is long. What you might not fully appreciate is why it's long, and what that means for how you build your go-to-market strategy.
Healthcare purchasing decisions involve a staggering number of stakeholders. Research from Harvard Business Review found that B2B buying groups have grown to an average of 6.8 people, and that was across all industries. In healthcare, where clinical, administrative, compliance, and IT teams all weigh in, that number climbs higher. Some enterprise deals involve 12 to 15 distinct voices before a contract is signed. The sales cycle routinely stretches past 13 months.
Most GTM strategies aren't designed for this. They're designed for a simpler version of reality: one where you identify the decision-maker, craft a pitch, and move through a linear funnel. That version doesn't exist in healthcare.
What a Homogenous Strategy Costs You
When you apply one playbook to a buying group that includes a VP of Operations, a Chief Nursing Officer, a clinical department head, and a procurement director, you get meetings. You don't get deals.
The reason is structural. Each of those people evaluates your product through a different lens. The operations leader cares about system efficiency and ROI. The clinical department head is thinking about whether this will disrupt workflows, whether the evidence holds up, and what their staff will think. The CNO is weighing patient impact and nursing bandwidth. Procurement wants to know about contract terms and vendor risk.
A single message can't serve all of them. And yet, this is the approach most healthtech companies try. They build one pitch deck, one set of talking points, one case study, and push it across the entire buying committee, with little-to-no audience customization. The result: the business buyer moves forward while the clinical evaluator quietly disengages. The deal stalls, and no one is really sure why.
What a "Clinical Layer" Actually Means
A clinical layer isn't a persona slide in your pitch deck. It's the integration of clinical evaluation logic into every part of your go-to-market motion: how you message, which channels you use, when you engage, what your reps say in the room, and how you measure what's working.
Think of it this way: your GTM strategy already has a commercial layer. You've mapped the business case, built ROI calculators, and trained reps to handle procurement objections. The clinical layer applies that same rigor to the clinical side of the buying process. It accounts for how clinicians evaluate, what they need to hear, where they're reachable, and what makes them disengage.
This isn't about adding "clinical content" to your website. It's about rethinking the underlying architecture of your sales motion so that clinicians are woven into the plan, not bolted on after the deal stalls.
Six Places Your GTM Needs Clinical Input
Most healthtech companies that struggle with clinician engagement aren't failing in one place. They're failing in several, and the failures compound. Here are six areas where clinical input changes the outcome.
1. Know Who Actually Makes the Decision
Mapping the buying process by title misses the point. A "Director of Pharmacy" at one health system might have final purchasing authority. At another, that same title is an influencer with no budget control, but veto power over anything that touches clinical workflows.
What matters is mapping how the decision actually gets made. Who are the clinical stakeholders? Are they buyers, influencers, evaluators, or blockers? Where do they enter the process, and what kind of power do they hold? A title is not a role in the decision. The goal is a decision map, not a contact list.
When this step is skipped, companies target the wrong person or the right person with the wrong framing. Deals stall at stages the team didn't know existed.
2. Build Messaging Clinicians Won't Ignore
Clinicians and administrators need fundamentally different messages. A clinical evaluator reading ROI-first messaging will tune out before the second paragraph. They're thinking about patient outcomes, whether the evidence holds up under scrutiny, how this affects their daily workflow, and whether or not you actually understand their world.
That last point is easy to underestimate. AHRQ's research on health IT implementation emphasizes that understanding workflow impact is one of the critical factors in successful technology adoption. Imprecise clinical language, or language that focuses on organizational metrics instead of individual clinical impact, creates a trust gap that's very difficult to close.
Each stakeholder type needs its own message. A business buyer and a clinical evaluator reading the same pitch is not efficiency. It's a structural failure.
3. Reach Clinicians Where They're Receptive
Access isn't just about finding the right email address. It's about reaching the right person, in the right setting, through the right pathway, at a moment when they're most open to the conversation.
Cold LinkedIn outreach to clinicians who don't use LinkedIn for vendor conversations wastes everyone's time. So does showing up at a conference with no system behind the booth. Good access strategy means understanding where clinicians are most receptive to considering new products, and being honest about where they aren't.
Timing matters too. Reaching a nurse manager the week before a Joint Commission survey is reaching a nurse manager who has no bandwidth for your product, no matter how good it is. Context and channel have to be calibrated together.
4. Give Your Sales Team Clinical Talk Tracks
Your reps probably know how to handle procurement objections. Do they know how to handle a clinical department head who says, "We tried something like this two years ago, and it made charting take twice as long"?
Clinical objections are different from business objections. They're rooted in workflow experience, evidence standards, and professional identity. A rep who responds to a clinical concern with a business answer signals that the company doesn't understand the clinician's reality. That signal is hard to undo.
The playbook needs clinical talk tracks, objection handling tailored to how clinicians push back, and supporting materials that hold up under clinical scrutiny. This also means designing for what happens after the signature. If the sales motion doesn't prepare clinical stakeholders for onboarding and adoption, what collapses post-close was never built into the deal.
5. Track Where Clinicians Drop Off
If you're not measuring clinical engagement separately from business engagement, you're flying blind. You might see a deal progressing through procurement while the clinical evaluator has already decided this isn't worth their time.
Build measurement into the motion from day one. Where are clinicians engaging? Where are they going silent? Which messages get responses from clinical stakeholders and which get ignored? Research on healthcare technology implementation consistently finds that adoption remains limited in part because feedback loops between clinical users and implementation teams are weak or nonexistent.
Tracking clinical engagement as its own data stream lets you diagnose problems before they kill the deal, not after.
6. Revisit and Adjust
A GTM strategy is not a one-time build. The clinical landscape shifts. Stakeholder priorities change. What worked in the first three months may not work in the next three.
Measure against the KPIs you defined before launch. What's working? What's stalling? What shifted in the clinical audience or the competitive environment? Then feed those findings back into the system. Reassess the decision map. Refresh messaging. Adjust the access strategy. The teams that compound early wins are the ones that treat their GTM motion as a loop, not a line.
Adoption Failure Is a Sales Design Problem
Here's the thing that doesn't get said enough: most post-sale adoption failures aren't product failures. They're sales design failures.
When a pilot collapses because nurses weren't prepared, or because the champion who signed the contract has no relationship with the end users who have to adopt the product, the root cause is upstream. Clinical stakeholders weren't identified or engaged during the sale. Onboarding wasn't designed around individual workflow friction. Nobody built a clinician-specific adoption plan.
Deloitte's analysis of health tech investment trends highlights that extended sales cycles and the gap between pilot and scale are persistent challenges for healthtech companies. The companies that clear this hurdle are the ones that design for post-sale adoption from inside the sales motion, not as an afterthought once the contract is signed.
The gap between pilot and full contract is where most healthtech revenue dies. And in most cases, that gap was baked into the deal from the beginning.
What This Looks Like in Practice
Take a healthtech company selling a clinical workflow tool to hospital systems. Without a clinical layer, the motion looks something like this:
Marketing generates leads through LinkedIn ads targeting VP-level titles
Sales sends a pitch deck built around ROI and efficiency gains
A demo is scheduled with the operations team
The deal moves to procurement
Somewhere during contracting, a clinical leader asks questions nobody prepared for
The deal stalls for months, and eventually dies or closes at a fraction of the original scope
With a clinical layer built in from the start, that same motion looks different:
The buying process is mapped by role and influence, not just title. Clinical evaluators, influencers, and potential blockers are identified early.
Messaging is built in parallel tracks: one for the business case, one calibrated for clinical stakeholders, addressing patient outcomes, workflow impact, and evidence.
Access strategy accounts for where clinical decision-makers are most receptive, and avoids channels they don't use for vendor conversations.
Reps carry clinical talk tracks and know how to handle clinical objections, not just procurement negotiations.
Clinical engagement is tracked as its own data stream, so the team sees when a clinical stakeholder disengages before the deal dies.
Post-sale adoption planning starts during the sale, not after the signature.
The difference isn't that one approach is fancier. It's that one approach accounts for how healthcare actually buys, and the other pretends it buys like every other industry.
If any of this sounds familiar, a good starting point is an honest look at where your current GTM motion accounts for clinical stakeholders and where it doesn't. We built a free self-assessment that walks you through exactly that, covering your messaging, access strategy, and sales enablement through a clinical lens. It takes about five minutes and gives you a clear read on where the gaps are.
If you want more on how clinicians evaluate products, how buying committees actually work in healthcare, and what to do about it, our newsletter covers this twice a month.